Pivotal (Spain)

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Niki Karachaliou, María González‐Cao, Guillermo Crespo et al. · Therapeutic Advances in Medical Oncology · 2018 · 274 citations · Full text

Medicine, Immunology, Oncology +17

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Imane Chaib, Niki Karachaliou, Sara Pilotto et al. · JNCI Journal of the National Cancer Institute · 2017 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí et al. · Annals of Oncology · 2006 · 204 citations · Full text

Medicine, Oncology, Pharmacology +17